In the largest investigation to date of germline genetic testing for patients with MpBC, this cohort study found a 16.8% prevalence of clinically meaningful PGVs in breast cancer susceptibility genes, mostly in BRCA1. This represents a substantial population of patients with MpBC found to have PGVs. This evidence concerns the gene BRCA1 and breast cancer.